GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (NAS:GNFT) » Definitions » Long-Term Capital Lease Obligation

Genfit (Genfit) Long-Term Capital Lease Obligation : $5.24 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Genfit Long-Term Capital Lease Obligation?

Genfit's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.24 Mil.

Genfit's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($5.44 Mil) to Sep. 2023 ($0.00 Mil) but then increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($5.24 Mil).

Genfit's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($6.76 Mil) to Dec. 2022 ($5.86 Mil) and declined from Dec. 2022 ($5.86 Mil) to Dec. 2023 ($5.24 Mil).


Genfit Long-Term Capital Lease Obligation Historical Data

The historical data trend for Genfit's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genfit Long-Term Capital Lease Obligation Chart

Genfit Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.30 9.79 6.76 5.86 5.24

Genfit Quarterly Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.86 5.44 - 5.24

Genfit  (NAS:GNFT) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Genfit Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Genfit's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Genfit (Genfit) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (NAS:GNFT) » Definitions » Long-Term Capital Lease Obligation
Traded in Other Exchanges
Address
Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.